Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The stock is up by about 191% over the past five years compared to a 94% gain from the benchmark S&P 500 index.

Wall Street likes the company's promising pipeline ... this weight-loss drug stock could more than 3x over the next 12 months -- and it's not Eli Lilly or Novo Nordisk. The great expectations for Viking Therapeutics aren't limited to only a few outlier ...